Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hewison

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 15, 2010
Tuberculosis treatment in a refugee and migrant population: 20 years of experience on the Thai-Burmese borderA Minetti, O Camelique, K Hsa Thaw, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?M Bastard, E Sanchez-Padilla, A Hayrapetyan, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 22, 2016
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort studyM Bonnet, M Bastard, P du Cros, et al.
Public Health Action|June 23, 2022
Integrating hepatitis C treatment into multidrug-resistant TB careO Kirakosyan, N Melikyan, J Falcao, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 25, 2017
Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countriesL Guglielmetti, C Hewison, Z Avaliani, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 20, 2018
Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and GeorgiaC Hewison, M Bastard, N Khachatryan, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from ArmeniaE Ardizzoni, W Mulders, M De Diego Fuertes, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|November 11, 2020
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TBV Cox, L McKenna, R Acquah, et al.
IJTLD Open|March 17, 2025
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacyL Kuksa, C Andrejak, B Haecker, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TBC Zeng, C D Mitnick, C Hewison, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 15, 2010
Tuberculosis treatment in a refugee and migrant population: 20 years of experience on the Thai-Burmese borderA Minetti, O Camelique, K Hsa Thaw, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?M Bastard, E Sanchez-Padilla, A Hayrapetyan, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 22, 2016
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort studyM Bonnet, M Bastard, P du Cros, et al.
Public Health Action|June 23, 2022
Integrating hepatitis C treatment into multidrug-resistant TB careO Kirakosyan, N Melikyan, J Falcao, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 25, 2017
Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countriesL Guglielmetti, C Hewison, Z Avaliani, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 20, 2018
Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and GeorgiaC Hewison, M Bastard, N Khachatryan, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from ArmeniaE Ardizzoni, W Mulders, M De Diego Fuertes, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|November 11, 2020
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TBV Cox, L McKenna, R Acquah, et al.
IJTLD Open|March 17, 2025
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacyL Kuksa, C Andrejak, B Haecker, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TBC Zeng, C D Mitnick, C Hewison, et al.
Pageof 3